首页|期刊导航|Oncology Research|SIK2 inhibitor SIC-19 enhances the sensitivity of PARP inhibitors in triple-negative breast cancers and pancreatic cancers

SIK2 inhibitor SIC-19 enhances the sensitivity of PARP inhibitors in triple-negative breast cancers and pancreatic cancers

QIAN LI SHUNPENG ZHU MINGXIAN ZHU FANG WANG JINHUA ZHOU

Oncology Research2025，Vol.33Issue(7)：P.1757-1767,11.

Oncology Research2025，Vol.33Issue(7)：P.1757-1767,11.DOI:10.32604/or.2025.062539

SIK2 inhibitor SIC-19 enhances the sensitivity of PARP inhibitors in triple-negative breast cancers and pancreatic cancers

QIAN LI ¹SHUNPENG ZHU ¹MINGXIAN ZHU ²FANG WANG ¹JINHUA ZHOU¹

作者信息

1. Department of Obstetrics and Gynecology,The First Affiliated Hospital of Soochow University,Suzhou,215006,China
2. Department of Pharmacology,College of Pharmaceutical Sciences,Soochow University,Suzhou,215009,China
折叠

摘要

关键词

Triple negative breast cancer(TNBC)/PARP inhibitor/Salt-inducible kinase 2(SIK2)/Pancreatic cancer(PC)/SIC-19

分类

医药卫生

引用本文复制引用

QIAN LI,SHUNPENG ZHU,MINGXIAN ZHU,FANG WANG,JINHUA ZHOU..SIK2 inhibitor SIC-19 enhances the sensitivity of PARP inhibitors in triple-negative breast cancers and pancreatic cancers[J].Oncology Research,2025,33(7):P.1757-1767,11.

基金项目

supported by the National Natural Science Foundation of China to Jinhua Zhou(Nos.82172609) （Nos.82172609）

Jiangsu Social Development Project(Nos.BE2022729). （Nos.BE2022729）

Oncology Research

ISSN：0965-0407

访问量0

下载量0

段落导航